Last updated on February 2019

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies


Brief description of study

This study is a Phase 1, Non-randomized, Open-label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo programmed mobilized peripheral blood cells) Versus Non-programmed mobilized peripheral blood cells for Allogeneic Hematopoietic Cell Transplantation (HCT) in Adult Subjects Aged 18 to 70 years with Hematologic Malignancies. A maximum of 70 total eligible subjects will be enrolled and treated in the trial at approximately 15-20 centers in the US and EU.

Clinical Study Identifier: NCT02743351

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.